Reading IMNN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IMNN free→Reading IMNN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IMNN free→QuarterlyIQ Insights · IMNN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Imunon, Inc. (the “Company”) held on June 16, 2026, the Company’s stockholders approved an amendment to the IMUNON, Inc. 2018 Stock Incentive Plan (the “Plan”), which amendment was approved by the Company’s board of directors on February 27, 2026. The amendment increased the aggre…
Entry into a Material Definitive Agreement. On June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) 250 shares (the “ Preferred Shares ”) of the Company’s Series A Preferred Stock, par value $0.01 per share (the “ Series A Preferred Stock ”), at a price of $10,000 per share,…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of Registrant. The information contained in
by reference. The Preferred Shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”).
Results of Operations and Financial Condition. On May 12, 2026, Imunon, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On May 5, 2026, Imunon, Inc. announced it would hold a conference call on May 12, 2026 to discuss its financial results for the quarter ended March 31, 2026 and provide a business update. The conference call will also be broadcast liv…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Compensatory Arrangements of Certain Officers. On May 1, 2026, Imunon, Inc. (the “Company”) entered into change of control agreements (“CIC Agreements”), following approval of the Compensation Committee of the Board of Directors (the “Board”) of the Company with each of Stacy Lindborg, the Company’s Chief Executive Officer and President, Dougla…
Results of Operations and Financial Condition. On March 31, 2026, Imunon, Inc. issued a press release reporting its financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On March 24, 2026, Imunon, Inc. announced it would hold a conference call on March 31, 2026 to discuss its financial results for the year ended December 31, 2025 and provide a business update. The conference call will also be broadc…
Other Events. On March 23, 2026, Imunon, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to register an additional $7,000,000 of shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between the Compa…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Retirement of Chief Scientific Officer On February 2, 2026, Khursheed Anwer informed Imunon, Inc. (the “Company”) of his intent to retire as Executive Vice President and Chief Scientific Officer from the Company, and Dr. Anwer’s employment with the Company will end, effective February 20, 2026 (the “Retirement Date”). Dr. Anwer’s departure is witho…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Interim Chief Financial Officer On January 7, 2026, Imunon, Inc. (the “Company”) announced that Kimberly Graper, its interim Chief Financial Officer, will be resigning from her role effective January 14, 2026. Ms. Graper’s departure is to pursue an attractive career opportunity and is without any disagreements with management. Her no…
Entry into a Material Definitive Agreement. On December 29, 2025, Imunon, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused institutional investor (the “Purchaser”) for a registered direct offering (the “Offering”) of (i) 330,000 shares (the “Shares”) of its common stock, par value $0.01 per share (“Common Stock”), (ii) pre-funded warrants (the “Pre-funded Warrants”) in lieu of Shares, to the…
Results of Operations and Financial Condition. On November 13, 2025, Imunon, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On November 6, 2025, Imunon, Inc. announced it would hold a conference call on November 13, 2025 to discuss its financial results for the quarter ended September 30, 2025 and provide a business update. The conference call wil…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 27, 2025, Imunon, Inc. (the “Company”) received a written notification from the Nasdaq Hearings Panel indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
Results of Operations and Financial Condition. On August 5, 2025, Imunon, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On July 29, 2025, Imunon, Inc. announced it would hold a conference call on August 5, 2025 to discuss its financial results for the quarter ended June 30, 2025 and provide a business update. The conference call will also be broadcast…
Other Events. On July 28, 2025, Imunon, Inc. (the “Company”), issued a press release announcing that the Company’s Board of Directors approved a 15% stock dividend, 0.15 shares of common stock (the “Stock Dividend”) per share of the Company’s issued and outstanding shares of common stock, par value $0.01 per share (the “Common Stock”), and per each common stock equivalent with dividend rights. The Board of Directors has fixed August 7, 2025 as the record date (the “Record Date”) for the Stock…
or Item 9.01; and ● Description of Securities of the Company, incorporated herein by reference to Exhibit 4.7 to the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2024. 19 In addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offering (excluding any information furnished rather than filed), shall be deemed to be incorporated by reference into this prospectus. An…
Other Events. On July 22, 2025, Imunon, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to register an additional $4,500,000 of shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between the Compan…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers At the Company’s 2025 Annual Meeting of Stockholders held on July 11, 2025 (the “Annual Meeting”), the Company’s stockholders approved an amendment to the IMUNON, Inc. 2018 Stock Incentive Plan (the “Plan”), which amendment was approved by the Company’s board of directors on March 14, 2025. The amendment increased the aggregate number of shares of c…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Delisting Notice As previously disclosed, on November 26, 2024, Imunon, Inc. (“the Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, for the previous 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price…
Material Modification to Rights of Security Holders. At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Imunon, Inc. (the “Company”) held on July 11, 2025, and as further described in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Termination of Chief Financial Officer On June 13, 2025, Imunon, Inc. (the “Company”) terminated the consulting agreement (as amended, the “Agreement”), dated April 15, 2024, by and between the Company and Monomoy Advisors, LLC, a financial advisory services firm (“Monomoy”), as well as David Gaiero’s service pursuant to the Agreement as the Compan…
Other Events. As previously disclosed, on November 26, 2024, Imunon, Inc. (“the Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, for the previous 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Ma…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Delisting Notice As previously disclosed, on November 26, 2024, Imunon, Inc. (“the Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, for the previous 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price…
Entry into a Material Definitive Agreement. On May 23, 2025, Imunon, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 2,777,779 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), (ii) pre-funded warrants (the “Pre-Fu…
Other Events. The Company issued a press release announcing the pricing of the Private Placement on May 23, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. Cautionary Note Regarding Forward-Looking Statements Except for the factual statements made herein, information contained in this report consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncer…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.